Exact Sciences rises, Abbott falls on $23 billion buyout deal

Abbott Laboratories

20/11/2025 17:00

updates prices to regular session, adds Wednesday trading details

** Shares of cancer test maker Exact Sciences EXAS.O rise 17.2% to $101 while medical device maker Abbott Laboratories ABT.N fell 1.1% to $124.70

** ABT, which was one of the weakest stocks in the S&P 500 healthcare index .SPXHC on Thursday, says it will acquire EXAS for up to $23 billion, including $21 billion in equity, to tap into the fast-growing cancer diagnostics segment

** Under terms of the deal, ABT will acquire all outstanding shares of EXAS for $105 per share, a premium of 21.8% to EXAS' last closing price before the announcement.

** On Wednesday EXAS shares had risen 23.7% after a Bloomberg News report that Abbott was closing in on a deal with EXAS and ABT shares ended down almost 3% after the report. Thursday would be ABT's fourth straight day of losses.

** Deal expected to close in the second quarter of 2026

** Including the deal related rallies, shares in EXAS up ~80% YTD, while ABT up ~10% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))